Antiplatelets After Stenting

Guest: Malcolm Bell, M.D.

Host: Sharonne Hayes, M.D.

In this podcast, we discuss the rationale for shortening the duration of dual antiplatelet therapy after coronary stenting and continuing P2Y12 inhibitor in preference to continuing aspirin as monotherapy.  With this approach, the risk of significant bleeding is reduced significantly and with no corresponding increase in ischemic or thrombotic events.  This strategy is particularly attractive for patients who are considered to be at high-risk of bleeding or who suffer an actionable bleed. A P2Y12 inhibitor appears to more efficacious for long term secondary prevention than aspirin.

Topics Discussed:

• Changes in the use of dual antiplatelet therapy for patients undergoing coronary stenting.

Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices.

LinkedIn: Mayo Clinic Cardiovascular Services

No CME credit offered for this episode.

Podcast episode transcript found here.